Yipinhong subsidiary secures methylsulfate neostigmine injection registration

Guangzhou Lianrui Pharmaceutical Co., a wholly-owned subsidiary of Yipinhong Pharmaceutical Group, has received a drug registration certificate for Methylsulfate Neostigmine Injection from the National Medical Products Administration. This approval allows the company to market this chemical medicine, classified as a Class 3 drug, in the domestic market, having passed consistency evaluation. The product, an anticholinesterase drug, is indicated for reversing residual neuromuscular blockade, treating myasthenia gravis, postoperative functional abdominal distension, and urinary retention.

The registration certificate is valid until October 13, 2030, and the product has a shelf life of 24 months. According to Minaiwang data, the sales scale of Neostigmine in Chinese urban and county-level public hospitals in 2024 was approximately CNY 79,118万元. The drug will be sold in 4ml:2mg specifications, with packaging of 5 vials per box.

This milestone enhances Yipinhong's core competitiveness by enriching its product pipeline and categories. However, the company cautions investors that sales may be subject to market and environmental uncertainties, leading to risks of not meeting sales expectations.